| http://purl.uniprot.org/citations/20412098 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/20412098 | http://www.w3.org/2000/01/rdf-schema#comment | "WT1 is well-known to be a panleukemic marker that is expressed in 90% of acute myeloid leukemias (AML). Quantification of WT gene expression in bone marrow (BM) samples may be useful as a marker of minimal residual disease (MRD) during and after treatment for early prediction of relapse. We evaluated the validity of this AML-MRD marker after reduced intensity conditioning (RIC) allogeneic stem cell transplantation (SCT). The quantitative assessment of WT1 expression by real-time quantitative PCR (RQ-PCR) was measured in 25 patients (pts) with AML at diagnosis, at the time of RIC-SCT and after transplant at precise time points. All pts showed high WT1 levels at diagnosis with a mean of 4895 (SD 4462) and a median of 3679 (range 454-16,853) copies WT1/10(4) ABL. At transplant, 18/25 pts (72%) were in complete cytologic remission (CcR) and 7/25 (28%) had refractory AML. At the pre-SCT evaluation, BM samples from pts transplanted in CcR showed significantly lower WT1 expression levels compared to the samples from pts with refractory AML (p = 0.002). Median follow-up after RIC-SCT was 18 months (range 2-54). On 18 pts transplanted in CcR, those (17/18) who maintained CcR after RIC-SCT displayed a WT1 copy number persistently low during all the follow-up period. In patients who received RIC-SCT with active disease obtaining a sustained CcR after transplant (3/25), WT1 levels decreased to normal range in the first two months after RIC-SCT and remained low through the entire study period. All pts who relapsed after RIC-SCT (4/25) had a high WT1 copy number before the cytologic relapse. In 50% of these cases, an increase in WT1 expression was documented before molecular chimerism decreasing. With this experience, taking into account the limited number of pts, we confirmed a concordance between WT1 expression levels (measured by RQ-PCR at precise and sequential time points) and status of AML before and after RIC-SCT and we found a concordance between WT1 expression levels and hematopoietic chimerism status. Our data suggest that, in the RIC-SCT setting, the sequential and quantitative analysis of WT1 may be useful as a leukemia marker for monitoring MRD and as a predictor of overt AML cytologic relapse."xsd:string |
| http://purl.uniprot.org/citations/20412098 | http://purl.org/dc/terms/identifier | "doi:10.1111/j.1399-0012.2010.01251.x"xsd:string |
| http://purl.uniprot.org/citations/20412098 | http://purl.uniprot.org/core/author | "Fanin R."xsd:string |
| http://purl.uniprot.org/citations/20412098 | http://purl.uniprot.org/core/author | "Simeone E."xsd:string |
| http://purl.uniprot.org/citations/20412098 | http://purl.uniprot.org/core/author | "Candoni A."xsd:string |
| http://purl.uniprot.org/citations/20412098 | http://purl.uniprot.org/core/author | "Toffoletti E."xsd:string |
| http://purl.uniprot.org/citations/20412098 | http://purl.uniprot.org/core/author | "Chiozzotto M."xsd:string |
| http://purl.uniprot.org/citations/20412098 | http://purl.uniprot.org/core/author | "Gallina R."xsd:string |
| http://purl.uniprot.org/citations/20412098 | http://purl.uniprot.org/core/author | "Volpetti S."xsd:string |
| http://purl.uniprot.org/citations/20412098 | http://purl.uniprot.org/core/date | "2011"xsd:gYear |
| http://purl.uniprot.org/citations/20412098 | http://purl.uniprot.org/core/name | "Clin Transplant"xsd:string |
| http://purl.uniprot.org/citations/20412098 | http://purl.uniprot.org/core/pages | "308-316"xsd:string |
| http://purl.uniprot.org/citations/20412098 | http://purl.uniprot.org/core/title | "Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia."xsd:string |
| http://purl.uniprot.org/citations/20412098 | http://purl.uniprot.org/core/volume | "25"xsd:string |
| http://purl.uniprot.org/citations/20412098 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/20412098 |
| http://purl.uniprot.org/citations/20412098 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/20412098 |
| http://purl.uniprot.org/uniprot/#_A0A0H5AUY0-mappedCitation-20412098 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/20412098 |
| http://purl.uniprot.org/uniprot/#_A0FJ57-mappedCitation-20412098 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/20412098 |
| http://purl.uniprot.org/uniprot/#_A0FJ58-mappedCitation-20412098 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/20412098 |
| http://purl.uniprot.org/uniprot/#_A0A481V744-mappedCitation-20412098 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/20412098 |
| http://purl.uniprot.org/uniprot/#_A8MN20-mappedCitation-20412098 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/20412098 |
| http://purl.uniprot.org/uniprot/#_P19544-mappedCitation-20412098 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/20412098 |
| http://purl.uniprot.org/uniprot/#_Q6PI38-mappedCitation-20412098 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/20412098 |
| http://purl.uniprot.org/uniprot/#_Q6LBI3-mappedCitation-20412098 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/20412098 |